## Min-Soo Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4063375/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Whole-genome sequencing reveals KRTAP1-1 as a novel genetic variant associated with antidepressant treatment outcomes. Scientific Reports, 2021, 11, 4552.	3.3	3
2	Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study. Human Psychopharmacology, 2020, 35, 1-7.	1.5	9
3	Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. Asia-Pacific Psychiatry, 2020, 12, e12393.	2.2	16
4	The associations of TAC1 gene polymorphisms with major depressive disorder. Molecular and Cellular Toxicology, 2019, 15, 129-136.	1.7	1
5	Psychotropic drug-prescribing correlates of disorganized speech in Asians with schizophrenia: The REAP-AP study. Saudi Pharmaceutical Journal, 2019, 27, 246-253.	2.7	12
6	Concurrent antipsychotic use in older adults treated with antidepressants in Asia. Psychogeriatrics, 2019, 19, 333-339.	1.2	7
7	Concurrent benzodiazepine use in older adults treated with antidepressants in Asia. International Psychogeriatrics, 2019, 31, 685-691.	1.0	8
8	The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder. Psychiatry Research - Neuroimaging, 2018, 273, 25-34.	1.8	35
9	Interaction effects of oxytocin receptor gene polymorphism and depression on hippocampal volume. Psychiatry Research - Neuroimaging, 2018, 282, 18-23.	1.8	19
10	Physical comorbidities in older adults receiving antidepressants in Asia. Psychogeriatrics, 2018, 18, 351-356.	1.2	3
11	Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder. Scientific Reports, 2017, 7, 42621.	3.3	74
12	How many different symptom combinations fulfil the diagnostic criteria for major depressive disorder? Results from the CRESCEND study. Nordic Journal of Psychiatry, 2017, 71, 217-222.	1.3	42
13	A comparison of clinical characteristics of older adults treated with antidepressants in general and psychiatric hospitals in <scp>A</scp> sia. Psychogeriatrics, 2017, 17, 348-355.	1.2	2
14	Vesicular monoamine transporter 1 gene polymorphism and white matter integrity in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 138-145.	4.8	13
15	Precarious employment associated with depressive symptoms and suicidal ideation in adult wage workers. Journal of Affective Disorders, 2017, 218, 201-209.	4.1	52
16	TESC gene-regulating genetic variant (rs7294919) affects hippocampal subfield volumes and parahippocampal cingulum white matter integrity in major depressive disorder. Journal of Psychiatric Research, 2017, 93, 20-29.	3.1	42
17	Structural characteristics of the brain reward circuit regions in patients with bipolar I disorder: A voxel-based morphometric study. Psychiatry Research - Neuroimaging, 2017, 269, 82-89.	1.8	4
18	The association between substance P and white matter integrity in medication-naive patients with major depressive disorder. Scientific Reports, 2017, 7, 9707.	3.3	11

#	Article	IF	CITATIONS
19	Ageâ€related clinical characteristics of major depressive disorder in Koreans: Results from the CRESCEND study. Asia-Pacific Psychiatry, 2017, 9, e12292.	2.2	Ο
20	Local gyrification index in patients with major depressive disorder and its association with tryptophan hydroxylaseâ€2 ( <scp><i>TPH2</i></scp> ) polymorphism. Human Brain Mapping, 2017, 38, 1299-1310.	3.6	35
21	Prevalence and clinical characteristics of major depressive disorder (MDD) without depressed mood in Koreans with MDD: results from the CRESCEND study. Journal of Theoretical Social Psychology, 2017, 27, 435-438.	1.9	0
22	Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study. Clinical Psychopharmacology and Neuroscience, 2017, 15, 391-401.	2.0	2
23	Clinical Characteristics and Psychotropic Prescribing Patterns Associated with impaired Concentration in Asians with Depressive Disorders: The REAP-AD Study. Tohoku Journal of Experimental Medicine, 2017, 242, 151-156.	1.2	1
24	Clinical Validation of the Psychotic Depression Assessment Scale, Hamilton Depression Rating Scale-6, and Brief Psychiatric Rating Scale-5: Results from the Clinical Research Center for Depression Study. Psychiatry Investigation, 2017, 14, 568.	1.6	8
25	Clinical Significance of the Number of Depressive Symptoms in Major Depressive Disorder: Results from the CRESCEND Study. Journal of Korean Medical Science, 2016, 31, 617.	2.5	9
26	Potential Relationship between Season of Birth and Clinical Characteristics in Major Depressive Disorder in Koreans: Results from the CRESCEND Study. Yonsei Medical Journal, 2016, 57, 784.	2.2	11
27	Effects of a Polymorphism of the Neuronal Amino Acid Transporter SLC6A15 Cene on Structural Integrity of White Matter Tracts in Major Depressive Disorder. PLoS ONE, 2016, 11, e0164301.	2.5	42
28	Influence of Bcl I C/G (rs41423247) on hippocampal shape and white matter integrity of the parahippocampal cingulum in major depressive disorder. Psychoneuroendocrinology, 2016, 72, 147-155.	2.7	15
29	Suicidal thoughts/acts and clinical correlates in patients with depressive disorders in Asians: results from the REAP-AD study. Acta Neuropsychiatrica, 2016, 28, 337-345.	2.1	16
30	Brain-derived neurotrophic factor promoter methylation and cortical thickness in recurrent major depressive disorder. Scientific Reports, 2016, 6, 21089.	3.3	71
31	Regional cortical thinning of the orbitofrontal cortex in medication-naÃ⁻ve female patients with major depressive disorder is not associated with MAOA-uVNTR polymorphism. Annals of General Psychiatry, 2016, 15, 26.	2.7	8
32	Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea (the CRESCEND) Tj ETQq0 0 0 i	′gBT4∕Ωverl	ock1&0 Tf 50 2
33	Mental health service use in adults with suicidal ideation within a nationally representative sample of the Korean population. Journal of Affective Disorders, 2016, 193, 339-347.	4.1	19
34	International study on antidepressant prescription pattern at 40 major psychiatric institutions and hospitals in <scp>A</scp> sia: A 10â€year comparison study. Asia-Pacific Psychiatry, 2015, 7, 366-374.	2.2	23
35	Country variations in depressive symptoms profile in Asian countries: Findings of the Research on Asia Psychotropic Prescription (REAP) studies. Asia-Pacific Psychiatry, 2015, 7, 276-285.	2.2	12
36	Hazardous Drinking-Related Characteristics of Depressive Disorders in Korea: The CRESCEND Study. Journal of Korean Medical Science, 2015, 30, 74.	2.5	10

#	Article	IF	CITATIONS
37	Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine. Journal of Psychopharmacology, 2015, 29, 615-622.	4.0	10
38	Dimensional approach to symptom factors of major depressive disorder in Koreans, using the Brief Psychiatric Rating Scale: The Clinical Research Center for Depression of South Korea Study. Kaohsiung Journal of Medical Sciences, 2015, 31, 47-54.	1.9	9
39	Adjunctive Antipsychotic Prescriptions for Outpatients with Depressive Disorders in Asia: The Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) Study. American Journal of Psychiatry, 2015, 172, 684-685.	7.2	15
40	Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants. Behavioural Brain Research, 2015, 292, 116-124.	2.2	21
41	Gender differences in depressive symptom profiles and patterns of psychotropic drug usage in Asian patients with depression: Findings from the Research on Asian Psychotropic Prescription Patterns for Antidepressants study. Australian and New Zealand Journal of Psychiatry, 2015, 49, 833-841.	2.3	16
42	Association of brain-derived neurotrophic factor DNA methylation and reduced white matter integrity in the anterior corona radiata in major depression. Journal of Affective Disorders, 2015, 172, 74-80.	4.1	92
43	Is the BPRS-5 subscale of the psychotic depression assessment scale a reliable screening tool for psychotic depression?: Results from the CRESCEND Study. Journal of Affective Disorders, 2015, 174, 188-191.	4.1	16
44	Age-related differences in suicidality between young people and older adults with depression: data from a nationwide depression cohort study in Korea (the CRESCEND study). Comprehensive Psychiatry, 2015, 56, 85-92.	3.1	15
45	Gender Differences in the Clinical Characteristics of Psychotic Depression: Results from the CRESCEND Study. Clinical Psychopharmacology and Neuroscience, 2015, 13, 256-262.	2.0	2
46	Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition. Journal of Korean Medical Science, 2014, 29, 468.	2.5	13
47	Evidence-Based, Non-Pharmacological Treatment Guideline for Depression in Korea. Journal of Korean Medical Science, 2014, 29, 12.	2.5	38
48	Does Age at Onset of First Major Depressive Episode Indicate the Subtype of Major Depressive Disorder?: The Clinical Research Center for Depression Study. Yonsei Medical Journal, 2014, 55, 1712.	2.2	58
49	Impact of lingual gyrus volume on antidepressant response and neurocognitive functions in Major Depressive Disorder: A voxel-based morphometry study. Journal of Affective Disorders, 2014, 169, 179-187.	4.1	99
50	Renaming dementia – an East Asian perspective. International Psychogeriatrics, 2014, 26, 885-887.	1.0	15
51	Is the Psychotic Depression Assessment Scale a useful diagnostic tool?: The CRESCEND study. Journal of Affective Disorders, 2014, 166, 79-85.	4.1	23
52	Persistence and resolution of suicidal ideation during treatment of depression in patients with significant suicidality at the beginning of treatment: The CRESCEND study. Journal of Affective Disorders, 2014, 155, 208-215.	4.1	18
53	Personality traits associated with suicidal behaviors in patients with depression: The CRESCEND study. Comprehensive Psychiatry, 2014, 55, 1085-1092.	3.1	10
54	Cortical thickness, cortical and subcortical volume, and white matter integrity in patients with their first episode of major depression. Journal of Affective Disorders, 2014, 155, 42-48.	4.1	93

#	Article	IF	CITATIONS
55	Association between Glucocorticoid Receptor Methylation and Hippocampal Subfields in Major Depressive Disorder. PLoS ONE, 2014, 9, e85425.	2.5	125
56	Relationship of Temperament and Character in Remitted Depressed Patients with Suicidal Ideation and Suicide Attempts—Results from the CRESCEND Study. PLoS ONE, 2014, 9, e105860.	2.5	10
57	Distinctive Clinical Correlates of Psychotic Major Depression: The CRESCEND Study. Psychiatry Investigation, 2014, 11, 281.	1.6	30
58	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I) : Initial Choice of Antidepressant Treatment. Journal of Korean Neuropsychiatric Association, 2013, 52, 253.	0.5	4
59	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (III) : Dose Increment, Switching, Combination, and Augmentation Strategy in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 386.	0.5	2
60	Prevalence and Clinical Correlates of Insomnia in Depressive Disorders: The CRESCEND Study. Psychiatry Investigation, 2013, 10, 373.	1.6	47
61	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II) : Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 372.	0.5	2
62	Association between brainâ€derived neurotrophic factor <i><scp>V</scp>66<scp>M</scp></i> and treatment responses to escitalopram in patients with major depressive disorder. Asia-Pacific Psychiatry, 2012, 4, 241-249.	2.2	3
63	Plasma brain-derived neurotrophic factor level may contribute to the therapeutic response to eye movement desensitisation and reprocessing in complex post-traumatic stress disorder: a pilot study. Acta Neuropsychiatrica, 2012, 24, 384-386.	2.1	6
64	The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder. Psychiatry Investigation, 2012, 9, 391.	1.6	4
65	Pharmacogenetics in the treatment of depression in <scp>A</scp> sia. Asia-Pacific Psychiatry, 2011, 3, 107-108.	2.2	1
66	As a leader of psychiatry in Korea. Asia-Pacific Psychiatry, 2010, 2, 178-178.	2.2	0
67	Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression. Asia-Pacific Psychiatry, 2009, 1, 143-151.	2.2	1
68	Possible association between G-protein β3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia. Acta Neuropsychiatrica, 2007, 19, 351-356.	2.1	12
69	Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants. Drugs of Today, 2007, 43, 569.	1.1	11
70	The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD): Report of the Korean Society of Depressive and Bipolar Disorders. International Journal of Psychiatry in Clinical Practice, 2006, 10, 186-194.	2.4	14
71	No association between the brainâ€derived neurotrophic factor gene Val66Met polymorphism and postâ€traumatic stress disorder. Stress and Health, 2006, 22, 115-119.	2.6	38
72	The pharmacogenetics of antidepressant treatments for depressive disorders. Drug Development Research, 2005, 65, 170-178.	2.9	5

#	Article	IF	CITATIONS
73	Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Current Medical Research and Opinion, 2005, 21, 1369-1375.	1.9	21
74	CORRESPONDENCE. Australasian Psychiatry, 2004, 12, 290-290.	0.7	4
75	Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatric Genetics, 2004, 14, 111-115.	1.1	65
76	Coâ€edministration of sertraline and haloperidol. Psychiatry and Clinical Neurosciences, 1998, 52, S193-8.	1.8	11
77	Pharmacogenetics of ethnic populations. , 0, , 62-86.		2